The HBCCL panel provides a comprehensive resource of human B-cell cancer cell line data
Abstract
A more comprehensive characterization of the biological and molecular mechanisms underlying cancer cell lines remains essential. Despite the rise of complex experimental systems, cell line models persist as indispensable tools for high-throughput screening due to their robust proliferation kinetics and technical reproducibility with minimal ethical considerations. In this study, we introduce a data-comprehensive human B-cell cancer cell line (HBCCL) panel comprising 17 diffuse large B-cell lymphoma (DLBCL) cell lines and 18 multiple myeloma (MM) cell lines. Characteristics and disease-related molecular subtypes of the cell lines are presented as well as subclassification of DLBCL cell lines into LymphGen subtypes (BN2, MCD, N1, EZB, A53, and ST2). The panel includes integrated cell line datasets from drug dose–response screens (11 agents), genotyping, gene expression, miRNA, and proteomic profiling. The utility of this resource is illustrated with examples of analyses applicable to investigating molecular mechanisms and drug responses in B-cell malignancies.
Related
- Variant Classification of a Non-Protein Coding Gene: ACMG/AMP Specifications for RMRP from the Clinical Genome Resource Severe Combined Immunodeficiency Disease Variant Curation Expert Panel
- Concordance between gambling disorder, alcohol use disorder, and other behavioural addictions provides evidence for a comprehensive approach to addictive behaviours: A multiple systematic review analysis
- HEALTHCARE RESOURCE UTILIZATION IN THE MANAGEMENT OF CHRONIC GRAFT VERSUS HOST DISEASE IN BRAZIL: RESULTS FROM A MULTI-REGIONAL DELPHI PANEL
- 47 AI-assisted cytometry panel design for cancer immunotherapy
- KRASG12S Positive Non‐Small Cell Lung Cancer Mimicking KRASG12C Positivity on the AmoyDx PCR Panel: A Case Report
BibTeX
@article{haraldsdottir2026hbccl,
title = {{The HBCCL panel provides a comprehensive resource of human B-cell cancer cell line data}},
author = {Hulda Haraldsdóttir and Rasmus Froberg Brøndum and Helle Høholt and Maja Z. Jakobsen and Martin Bøgsted and Allan Stensballe and Karen Dybkaer and Hanne Due},
journal = {Scientific Reports},
year = {2026},
month = oct,
doi = {10.1038/s41598-026-72106-9},
url = {https://www.nature.com/articles/s41598-026-72106-9},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - The HBCCL panel provides a comprehensive resource of human B-cell cancer cell line data
AU - Hulda Haraldsdóttir
AU - Rasmus Froberg Brøndum
AU - Helle Høholt
AU - Maja Z. Jakobsen
AU - Martin Bøgsted
AU - Allan Stensballe
AU - Karen Dybkaer
AU - Hanne Due
PY - 2026
DA - 2026/10/27
JO - Scientific Reports
DO - 10.1038/s41598-026-72106-9
UR - https://www.nature.com/articles/s41598-026-72106-9
AB - A more comprehensive characterization of the biological and molecular mechanisms underlying cancer cell lines remains essential. Despite the rise of complex experimental systems, cell line models persist as indispensable tools for high-throughput screening due to their robust proliferation kinetics and technical reproducibility with minimal ethical considerations. In this study, we introduce a data-comprehensive human B-cell cancer cell line (HBCCL) panel comprising 17 diffuse large B-cell lymphoma (DLBCL) cell lines and 18 multiple myeloma (MM) cell lines. Characteristics and disease-related molecular subtypes of the cell lines are presented as well as subclassification of DLBCL cell lines into LymphGen subtypes (BN2, MCD, N1, EZB, A53, and ST2). The panel includes integrated cell line datasets from drug dose–response screens (11 agents), genotyping, gene expression, miRNA, and proteomic profiling. The utility of this resource is illustrated with examples of analyses applicable to investigating molecular mechanisms and drug responses in B-cell malignancies.
SN - 2045-2322
ER -